ライフサイエンスコーパス: vaccinia

1 risk for adverse reactions (eg, progressive vaccinia).

2 sion in promoting the cell-to-cell spread of vaccinia.

3 however, reduces the cell-to-cell spread of vaccinia.

4 Emerging evidence from vaccinia and influenza A virus infections indicates that

5 ion and generation of specific peptides from vaccinia- and influenza A virus-encoded proteins.

6 : replication-deficient adenovirus; modified vaccinia Ankara (a poxvirus); protein with alum; and pro

7 Needle-free SL/B vaccination with modified vaccinia Ankara (MVA) and a recombinant trimeric gp120 p

8 denovirus serotype 26 (Ad26) prime, modified vaccinia Ankara (MVA) boost) and stimulation of TLR7 (To

9 r in combination with a multivalent modified vaccinia Ankara (MVA) Ebola vaccine also appear promisin

10 old range of an admixed recombinant modified vaccinia Ankara (MVA) expressing rhesus GM-CSF (MVA/GM-C

11 Modified Vaccinia Ankara (MVA) is a highly attenuated poxvirus ve

12 Attenuated poxvirus modified vaccinia Ankara (MVA) is a useful viral-based vaccine fo

13 of lactating rhesus monkeys with a modified vaccinia Ankara (MVA) prime/intramuscular (i.m.) protein

14 ffect of adding a booster dose of a modified vaccinia Ankara (MVA) strain, encoding the same Ebola vi

15 tein from a clinically proven safe, Modified Vaccinia Ankara (MVA) vector, thus averting the potentia

16 chimpanzee adenovirus (ChAdOx1) and modified vaccinia Ankara (MVA) vectors in prime-boost regimens to

17 vaccinated over 81 weeks with DNA, modified vaccinia Ankara (MVA), vesicular stomatitis virus (VSV),

18 r but peak magnitudes were lower in Modified Vaccinia Ankara (MVA)-boosted regimens.

19 zations with subunit Env protein or modified vaccinia Ankara (MVA)-vectored Env and subunit Env prote

20 We studied the capacity of modified vaccinia Ankara (MVA)-vectored vaccine expressing nucleo

21 g vaccine followed by intramuscular Modified Vaccinia Ankara (rMVA) booster vaccine, both expressing

22 cine (ChAd3-EBO-Z) and boosted with modified vaccinia Ankara Ebola Zaire-vectored (MVA-EBO-Z) vaccine

23 TG4010 is a modified vaccinia Ankara expressing MUC1 and interleukin 2.

24 effect of boosting of Malians with modified vaccinia Ankara expressing Zaire Ebola virus glycoprotei

25 enhanced, T and B cell responses to modified vaccinia Ankara vaccination in a nonhuman primate model

26 using PBMCs isolated on day 7 post-modified vaccinia Ankara vaccination, the earliest time point at

27 We administered Ad26, modified vaccinia Ankara vectors containing mosaic HIV-1 antigens

28 o nonhuman Great Ape Adenoviral and Modified Vaccinia Ankara vectors to generate a viral-vectored vac

29 ion with recombinant HCV adenoviral/modified vaccinia Ankara viral vectors.

30 e, intramuscular (i.m.) recombinant Modified Vaccinia Ankara Virus (MVA)-gag pol-IL-4R antagonist boo

31 immunogenicity of the viral vector modified vaccinia Ankara virus vectored Ebola Zaire vaccine (MVA-

32 B cell and Ab responses induced by modified vaccinia Ankara were extremely weak.

33 a recombinant attenuated poxvirus (modified vaccinia Ankara) expressing immunodominant CMV antigens.

34 Preliminary data using modified vaccinia Ankara-5T4 (MVA-5T4) in mCRC demonstrated that

35 irus type 26.ZEBOV (Ad26.ZEBOV) and modified vaccinia Ankara-BN-Filo (MVA-BN-Filo) vaccine regimen is

36 erologous Adenovirus type 26.ZEBOV, Modified Vaccinia Ankara-BN-Filo vaccine regimen, on primary huma

37 enicity evaluation of PENNVAX-G DNA/modified vaccinia Ankara-Chiang Mai double recombinant (MVA-CMDR)

38 es mucosally with HIV/SIV peptides, modified vaccinia Ankara-SIV (MVA-SIV), and HIV-gp120-CD4 fusion

39 We studied the capacity of Modified Vaccinia Ankara-vectored vaccine expressing nucleoprotei

40 After an i.m. modified vaccinia Ankara/Gag boost, we observed robust Gag-specif

41 A recombinant vaccinia-based method for expressing uptake transporters

42 We have reported that a vaccinia-based OV (Pexa-Vec) has shown good efficacy in

43 human somatostatin receptor 2 (hSSR2) in the vaccinia-based OV and tested viral constructs for their

44 , Sindbis, vesicular stomatitis, cowpox, and vaccinia, but not murine leukemia or adenovirus.

45 nhibits intravenously administered oncolytic vaccinia delivery to and consequent spread within the tu

46 s used for the detection of human papilloma, vaccinia, dengue, Ebola, influenza A, human immunodefici

47 fluorescent nanodiamonds (FNDs) coated with vaccinia envelope proteins as the model system.

48 Vaccinia H1-related phosphatase (VHR/DUSP3) is a member

49 Our observations with vaccinia have now demonstrated that RhoD recruits Pak6 t

50 L-deficient human cells, DNA viruses such as vaccinia, herpes simplex, and adenovirus induced increas

51 Vaccinia immune globulin (VIG) has been used therapeutic

52 Similarly, hSSR2-containing OV vaccinia infected and lysed cancer cells.

53 e further characterize the role of B1 during vaccinia infection to gain novel insights into its regul

54 es, which include the largest genomes in the vaccinia lineage and one true horsepox strain.

55 d complete vRNAP complexes of the prototypic Vaccinia poxvirus (Grimm et al., 2019; in this issue of

56 previously identified a nonsense mutation in Vaccinia-related kinase 1 (VRK1), R358X, as a cause of S

57 Vaccinia-related kinase 2 (VRK2) is known to negatively

58 These studies identify vaccinia-related kinase-2 (VRK2) as a candidate constitu

59 The human genome encodes two active Vaccinia-related protein kinases (VRK), VRK1 and VRK2.

60 Vaccinia-specific antibodies were maintained indefinitel

61 Vaccinia-specific antibodies were measured by ELISA.

62 In contrast, there was a significant loss in vaccinia-specific CD4+ T cell memory among HIV+ subjects

63 Vaccinia still induces actin tails in the absence of the

64 ance to immunotherapies, including oncolytic vaccinia virotherapy.

65 adults, with or without immunity to CMV and vaccinia virus (previous DryVax smallpox vaccination).

66 Vaccinia virus (VACV) A27 is a target for viral neutrali

67 The vaccinia virus (VACV) A56/K2 fusion regulatory complex a

68 tions that (i) the replication and spread of vaccinia virus (VACV) and herpes simplex virus type 1 (H

69 Using vaccinia virus (VACV) as a model organism for other Orth

70 In this study, we applied vaccinia virus (VACV) by scarification to IL-1R1 knockou

71 produced in excess in cells infected with a vaccinia virus (VACV) decapping enzyme mutant and by wil

72 Vaccinia virus (VACV) decapping enzymes and cellular exo

73 The vaccinia virus (VACV) E3 protein has been shown to be im

74 Vaccination with vaccinia virus (VACV) elicits heterotypic immunity to sm

75 The I2L open reading frame of vaccinia virus (VACV) encodes a conserved 72-amino-acid

76 Vaccinia virus (VACV) encodes an innate immune evasion p

77 Vaccinia virus (VacV) encodes two decapping enzymes (D9,

78 Vaccinia virus (VACV) envelope protein D8 is one of thre

79 Vaccinia virus (VACV) evades the host immune response by

80 This work reveals the prototypic poxvirus Vaccinia virus (VACV) exploits cellular retrograde trans

81 ses; instead, we identified mutations in two vaccinia virus (VACV) genes, A24R and A35R, either of wh

82 ically defined T cell epitopes recognized in vaccinia virus (VACV) infected C57BL/6 mice (expressing

83 -knockout CD8(+) TRM cells generated by skin vaccinia virus (VACV) infection were less effective at p

84 In establishing a respiratory infection, vaccinia virus (VACV) initially replicates in airway epi

85 Vaccinia virus (VACV) is a poxvirus, and the VACV D4 pro

86 The vaccinia virus (VACV) K1 protein has multiple immunomodu

87 elicited protective immunity.IMPORTANCE The vaccinia virus (VACV) K1 protein inhibits NF-kappaB acti

88 Vaccinia virus (VACV) keratitis is a serious complicatio

89 The vaccinia virus (VACV) M1 ankyrin (ANK) protein, a protei

90 f a novel apoptosis inhibitor encoded by the vaccinia virus (VACV) M1L gene.

91 PKRs were able to restrict replication of a vaccinia virus (VACV) strain that lacks the PKR inhibito

92 Oxford Nanopore Technologies to profile the vaccinia virus (VACV) transcriptome.

93 Poxviruses such as Vaccinia virus (VACV) undertake a complex cytoplasmic re

94 The 50% lethal intraperitoneal dose of vaccinia virus (VACV) was 3 PFU for CAST mice, whereas B

95 Vaccinia virus (VACV), a close relative of smallpox viru

96 arly every step in the reproductive cycle of vaccinia virus (VACV), a large DNA virus with about 200

97 Vaccinia virus (VACV), the prototype member of the poxvi

98 n of proteins on nascent DNA) to investigate vaccinia virus (VACV), the prototype poxvirus.

99 y plasmid can replicate in cells infected by vaccinia virus (VACV), the prototype poxvirus.

100 Vaccinia virus (VACV), the prototypical member of the po

101 Using vaccinia virus (VACV), the smallpox vaccine, we report t

102 Yet, in the case of vaccinia virus (VACV), which constitutes the vaccine use

103 We used vaccinia virus (VACV)--a gold standard vaccine--as the i

104 Using skin infections with vaccinia virus (VacV)-expressing model antigens, we foun

105 are antigen-transporting cells that generate vaccinia virus (VACV)-specific T-cell responses, yet how

106 ed among poxviruses, including A6 and A11 of vaccinia virus (VACV).

107 EdU) into nascent DNA in cells infected with vaccinia virus (VACV).

108 utations during serial passage of attenuated vaccinia virus (VACV).

109 ient (nude, nu/nu) BALB/c mice infected with vaccinia virus (VACV).

110 ster ovary (CHO) cells are nonpermissive for vaccinia virus (VACV).

111 Vaccinia virus (VACV; the prototype poxvirus) prefers gl

112 We determined that a K1L-less vaccinia virus (vDeltaK1L) was less pathogenic than wild

113 e epidermis known as eczema vaccinatum after vaccinia virus (VV) infection of the skin.

114 Here, we show that after resolution of skin vaccinia virus (VV) infection, antigen-specific circulat

115 Epicutaneous vaccinia virus (VV) infection, mimicking human smallpox

116 hocytic Choriomeningitis Virus (LCMV) WE and Vaccinia Virus (VV) infections with naive T(regs), we ob

117 ll responses were measured after anti-CD3 or vaccinia virus (VV) stimulation to measure T cells elici

118 Chimpanzee adenovirus-6 (AdC6) or -7 (AdC7), Vaccinia virus (VV), and DNA given by electroporation (D

119 In this study, we uncovered a means of vaccinia virus adaptation involving the accumulation of

120 e-prototype JX-594), a replication-competent vaccinia virus administered by intravenous injection, to

121 e membrane-wrapping step in morphogenesis of vaccinia virus and egress from the cell.

122 panied by increased viral resistance against vaccinia virus and influenza B virus infections.

123 res are also induced by two other pathogens (vaccinia virus and Listeria monocytogenes).

124 Efficient cell-to-cell spread of vaccinia virus and other orthopoxviruses depends on the

125 bisbenzimide derivatives are potent against vaccinia virus and other poxviruses but ineffective agai

126 This discovery identifies a weakness of vaccinia virus and suggests a possible direction to inte

127 bility to monkeypox virus, cowpox virus, and vaccinia virus and thus providing a unique model for stu

128 r of the Orthopoxvirus genus, which includes Vaccinia virus and Variola virus (the causative agent of

129 by extensively passaging the chorioallantois vaccinia virus Ankara (CVA) vaccine strain in chicken em

130 uential immunizations with DNA (D), modified vaccinia virus Ankara (MVA) (M), and protein immunogens,

131 impanzee adenovirus 63 (ChAd63) and modified vaccinia virus Ankara (MVA) and used to immunize mice in

132 Using a modified vaccinia virus Ankara (MVA) as a vaccine model, we chara

133 A DNA prime-modified vaccinia virus Ankara (MVA) boost vaccine has proven to

134 nuclear antigen EBNA1 followed by a modified vaccinia virus Ankara (MVA) booster, induced significant

135 priming with DNA and boosting with modified vaccinia virus Ankara (MVA) expressing HIV-1 Env on viru

136 ctors simian adenovirus 63 (ChAd63)-modified vaccinia virus Ankara (MVA) is the most potent inducer o

137 we show that a CD40L-adjuvanted DNA/modified vaccinia virus Ankara (MVA) simian immunodeficiency viru

138 M1L is absent in the attenuated modified vaccinia virus Ankara (MVA) strain of VACV, a strain tha

139 DCs or expressed from a recombinant modified vaccinia virus Ankara (MVA) vector, improved priming of

140 ic cellular immune responses to the modified vaccinia virus Ankara (MVA) vector.

141 The poxvirus strain modified vaccinia virus Ankara (MVA), a safe and efficient viral

142 Modified vaccinia virus Ankara (MVA), a widely used vaccine vecto

143 Modified vaccinia virus Ankara (MVA), an attenuated poxvirus, has

144 with different combinations of DNA, modified vaccinia virus Ankara (MVA), soluble gp140 protein, and

145 ific T cells induced by a DNA-prime modified vaccinia virus Ankara (MVA)-boost vaccination strategy,

146 ency virus (SHIV) and boosting with modified vaccinia virus Ankara (MVA)-SHIV vaccines in rhesus maca

147 onserved antigenic regions by using modified vaccinia virus Ankara (MVA).

148 mine if mucosal vaccination using a modified vaccinia virus Ankara expressing human immunodeficiency

149 We show that booster modified vaccinia virus Ankara immunization induced a distinct an

150 e questions in the context of a DNA/modified vaccinia virus Ankara SIV vaccine with and without gp140

151 V S and core antigen, followed by a modified Vaccinia virus Ankara vector to induce HBV-specific B- a

152 r SIVmac239 envelope-expressing DNA/modified vaccinia virus Ankara vector- and protein-based vaccinat

153 ectors, using simian adenovirus and modified vaccinia virus Ankara vectors.

154 far, well-described vectors such as modified vaccinia virus Ankara, complex adenovirus, vesicular sto

155 impanzee adenovirus 63, ChAd63, and modified vaccinia virus Ankara, MVA, expressing AgAPN1, Pfs230-C,

156 ized with SIVmac239-based DNA-prime/modified vaccinia virus Ankara-boost vaccine regimens that includ

157 from rabbits and RM given identical modified vaccinia virus Ankara-prime/gp120-boost immunization reg

158 ther a chimpanzee adenovirus 63 and modified vaccinia virus Ankara-vectored vaccine expressing a mult

159 second homologous immunization with modified vaccinia virus Ankara.

160 f this homolog during infection, we utilized vaccinia virus as a surrogate and showed that a vaccinia

161 protein toxins, potently prevented spread of vaccinia virus as well as monkeypox virus, a human patho

162 ures of core and complete vRNAP enzymes from Vaccinia virus at 2.8 angstrom resolution.

163 we present the crystal structure of H3 from vaccinia virus at a 1.9-A resolution.

164 and ovarian cancer models that an oncolytic vaccinia virus attracts effector T cells and induces PD-

165 The vaccinia virus B1 kinase is highly conserved among poxvi

166 The most well characterized role for the vaccinia virus B1 kinase is to facilitate viral DNA repl

167 The vaccinia virus B1 protein is a homolog of cellular vacci

168 The vaccinia virus B1 protein kinase is involved in promotin

169 This study focuses on the vaccinia virus B1 protein kinase, an enzyme that promote

170 viously characterized functions, B1 inhibits vaccinia virus B12 protein via a phosphorylation-depende

171 HIV-1 antigens, with one of them lacking the vaccinia virus B19 protein, an inhibitor of the type I i

172 The vaccinia virus B1R gene encodes a highly conserved prote

173 Thus, vDeltaK1L is the first vaccinia virus construct reported that caused a muted in

174 nsight into the role of D4 as a co-factor of vaccinia virus DNA polymerase and allows a better unders

175 Vaccinia virus early genes are transcribed immediately u

176 Vaccinia virus encodes three BTB-Kelch proteins: A55, C2

177 gainst intranasal challenge with recombinant vaccinia virus encoding p24.

178 e isolation and characterization of numerous vaccinia virus enzymes, determination of the cap structu

179 cinia virus as a surrogate and showed that a vaccinia virus expressing MC021L-HA in place of F13L-HA

180 Comparison of responses to vaccinia virus expressing OVA peptide SIINFEKL by wild-t

181 vides complete immune control of recombinant vaccinia virus expressing the same epitope if KCSRNRQYL

182 with a small-plaque phenotype.IMPORTANCE The vaccinia virus extracellular virion protein F13 is requi

183 rhtrs1-amplified viruses, there arose in two vaccinia virus genes mutations that improved viral repli

184 n and conferred CD8-mediated protection to a vaccinia virus genital challenge.

185 ORTANCE Previous studies have shown that the vaccinia virus glycoproteins A34 and B5 interact, and in

186 omologs of the Bcl-2 family of proteins, and vaccinia virus harbors antiapoptotic F1L that potently i

187 The smallpox vaccine using vaccinia virus has been highly successful, but it is sti

188 giosum virus, is predicted to encode several vaccinia virus homologs of EV-specific proteins, includi

189 modified by the insertion of the K1L and C7L vaccinia virus host range genes and express the clade C(

190 per by applying it to SIM and STED images of vaccinia virus in isolation and when engaged with host c

191 , we analyzed the responses of host cells to vaccinia virus infection at both the transcriptional and

192 minor groove of double-stranded DNA, inhibit vaccinia virus infection by blocking viral DNA replicati

193 This study highlights the fact that vaccinia virus infection can enhance cellular energy pro

194 Vaccinia virus infection causes a host shutoff that is m

195 In this study, with vaccinia virus infection in mice, we show that OX40 was

196 dependent of infection or during a surrogate vaccinia virus infection to identify how MC159 prevented

197 infection with either virus, after a cleared vaccinia virus infection, and during a persistent/latent

198 f oxidative phosphorylation increased during vaccinia virus infection, while inhibition of the cellul

199 cific CD8(+) T cells responses to subsequent vaccinia virus infection.

200 regulation of the CD8(+) T cell response to vaccinia virus infection.

201 ncreased and accelerated mortality following vaccinia virus infection.

202 most bone marrow T cells activate 3 d after vaccinia virus infection.

203 dly increase translation in the first day of vaccinia virus infection.

204 LECs toward MPECs, during the acute phase of vaccinia virus infection.

205 ty to localize infected cells and to control vaccinia virus infection.

206 which accelerates clearance of epicutaneous vaccinia virus infection.

207 mune detection pathways, we performed serial vaccinia virus infections in primary human cells.

208 The achieved LOD for vaccinia virus is 10(4) particles in 1 mL of sample.

209 Vaccinia virus is a powerful model to study antibody res

210 present evidence that the impact of VRK2 on vaccinia virus is largely independent of BAF phosphoryla

211 Here, we show that the membrane of vaccinia virus is organized into distinct functional dom

212 On the basis of these results, vaccinia virus keratitis is significantly different from

213 factor (IRF) activation and ISG responses to vaccinia virus lacking F17 in both macrophages and lung

214 nd D10, but not of either enzyme alone, halt vaccinia virus late protein synthesis and inhibit virus

215 that B1 is required at another stage of the vaccinia virus life cycle.

216 Thus, vaccinia virus makes novel use of the retrograde transpo

217 revealed that this protein is essential for vaccinia virus morphogenesis and that its absence result

218 We characterized a mouse model of vaccinia virus ocular disease using C57BL/6 mice and str

219 fected cells after administration to mice of vaccinia virus or Zika virus.

220 mass spectrometry to identify more than 170 vaccinia virus pMHCI presented on infected mouse cells.

221 Vaccinia virus polymerase holoenzyme is composed of the

222 Crystal structures of vaccinia virus poxin in pre- and post-reactive states de

223 t rabbits immunized with a novel recombinant vaccinia virus prime-gp120 protein boost regimen generat

224 Vaccinia virus protein A49 inhibits NF-kappaB activation

225 described a novel role for B1 in inhibiting vaccinia virus protein B12, which otherwise impedes an e

226 We now demonstrate that the vaccinia virus protein F11, which localizes to the plasm

227 logues from other poxviruses, but not in the vaccinia virus proteins C2 or F3.

228 Five conserved vaccinia virus proteins, referred to as Viral Membrane A

229 ide evidence for the phosphoglycosylation of vaccinia virus proteins.

230 n and luciferase reporters demonstrated that vaccinia virus recognized MOCV intermediate and late pro

231 depend on host cells to provide, to support vaccinia virus replication during a host shutoff.IMPORTA

232 deletion of the poxin gene (B2R) attenuates vaccinia virus replication in vivo.

233 the beginning of the 1980s, research on the vaccinia virus replication mechanism has basically stall

234 maintenance of its function is important for vaccinia virus replication.

235 horylation function significantly suppressed vaccinia virus replication.

236 ilability plays a critical role in efficient vaccinia virus replication.

237 rce to fuel the tricarboxylic acid cycle for vaccinia virus replication.

238 lysis, we found that the fusion machinery of vaccinia virus resides exclusively in clusters at virion

239 Vaccinia virus ribosome-associated mRNA sequences were d

240 Poxviruses, myxoma virus and vaccinia virus specifically, utilize a virus-encoded hos

241 measured after anti-CD3 stimulation or after vaccinia virus stimulation to measure T cells elicited a

242 The groups were then boosted with either the vaccinia virus strain NYVAC or a variant with improved r

243 ion-competent, attenuated recombinant of the vaccinia virus strain NYVAC.

244 ection of C57BL/6 mice with 1 x 10(7) PFU of vaccinia virus strain WR results in blepharitis, corneal

245 e B21/22 family glycoproteins not encoded by vaccinia virus strains used as vaccines.

246 In this study, we show across a range of vaccinia virus strains, including the current clonal sma

247 more resistant to respiratory infection with vaccinia virus than wild-type mice.

248 l Medicine, Park et al. develop an oncolytic vaccinia virus that introduces truncated CD19 expression

249 ved in isolates from an outbreak of zoonotic vaccinia virus that occurred in Brazil.

250 antiviral protein PKR, enabled a recombinant vaccinia virus to replicate in resistant cells from huma

251 During its egress, vaccinia virus transiently recruits AP-2 and clathrin af

252 uct a high-resolution genome-wide map of the vaccinia virus translatome.

253 irst-ever use of tecovirimat as a preemptive vaccinia virus treatment strategy during induction chemo

254 First, we demonstrate that vaccinia virus uniquely requires VRK2 for viral replicat

255 of aggressive melanomas induced by oncolytic Vaccinia virus using RNA sequencing and found substantia

256 deep study of the covalent structure of the vaccinia virus virion using the various tools of contemp

257 xamine the protein covalent structure of the vaccinia virus virion.

258 We report here that the engineered oncolytic vaccinia virus VVWR-TK(-)RR(-)-Fcu1 can induce immunogen

259 y 10 passage rounds, the starting attenuated vaccinia virus was displaced by viruses with one fixed m

260 Vaccinia virus was made famous by being the virus used i

261 , we replaced the F13L open reading frame in vaccinia virus with an epitope-tagged version of MC021L.

262 ss-of-function analysis, we demonstrate that vaccinia virus's dependence on VRK2 is only observed in

263 immune-deficient (nu/nu) mice infected with vaccinia virus, a model of smallpox.

264 at causes a persistent/latent infection, and vaccinia virus, a poxvirus that is cleared by the host.

265 es of fatty acid in the diet on infection by vaccinia virus, an acute infection that begins in the re

266 vo from mRNA synthesized in the cytoplasm by vaccinia virus, and hence cannot be spliced.

267 uses including Herpes Simplex Virus-1 and-2, Vaccinia virus, and Zika virus through a type I interfer

268 /182R with a functional version derived from vaccinia virus, B13R Our results show that MVA-B13R sign

269 onocytogenes, vesicular stomatitis virus, or Vaccinia virus, but dispensable in the case of mouse cyt

270 gression are arrested in cells infected with vaccinia virus, but mass fluctuations continue until cel

271 n a murine model of cutaneous infection with vaccinia virus, dermal gammadelta T cell numbers increas

272 aa 21-84), a recombinant envelope protein of vaccinia virus, for glycosaminoglycans (GAGs)-specific t

273 on, and in the case of influenza B virus and vaccinia virus, ISG15 conjugation has been shown to rest

274 l involving serial passages of an attenuated vaccinia virus, rapid acquisition of inactivating frames

275 Vaccinia virus, the prototypic member of the poxviruses,

276 When compared to vaccinia virus, this archival strain contained the same

277 e inhibitor 1 (SPI-1) of rabbitpox virus and vaccinia virus, two closely related orthopoxviruses, pre

278 From our work with vaccinia virus, we give first insights into the overall

279 ymphocytic choriomeningitis virus (LCMV) and vaccinia virus, where the pathogens are cleared, but it

280 TRAP is delivered using adenovirus- and vaccinia virus-based vectors in a prime-boost regime.

281 virion preparations, >88% of the theoretical vaccinia virus-encoded proteome was detected with high c

282 RNAs were translationally upregulated during vaccinia virus-induced host protein synthesis shutoff.

283 ured the host mRNA translation rate during a vaccinia virus-induced host shutoff by analyzing total a

284 ns may be selectively synthesized during the vaccinia virus-induced host shutoff.

285 s rapidly and preferentially associated with vaccinia virus-infected cells in the LN paracortex, whic

286 ia virus B1 protein is a homolog of cellular vaccinia virus-related kinases (VRKs) and is needed for

287 xhibits a remarkable degree of similarity to vaccinia virus-related kinases (VRKs), a family of cellu

288 g of three conserved cellular enzymes called vaccinia virus-related kinases (VRKs).

289 scent formation, including the A6 protein of vaccinia virus.

290 merous RNA viruses but enhances the entry of vaccinia virus.

291 ized against foreign rhesus D alloantigen or vaccinia virus.

292 the movement of microbial pathogens such as vaccinia virus.

293 athway components for cell-to-cell spread of vaccinia virus.

294 mory CD8(+) T cells following infection with vaccinia virus.

295 sing data from humans, domestic pigeons, and vaccinia virus.

296 the crystal structure of the H7 protein from vaccinia virus.

297 peptide-pulsed dendritic cells, recombinant vaccinia viruses encoding full-length T Ag or epitope mi

298 res of the antitumor properties of oncolytic vaccinia viruses, all of which can be amplified by the m

299 uitment of leukocytes, which is unique among vaccinia viruses.

300 -electron microscopy (cryo-EM) structures of Vaccinia vRNAP in the form of a transcribing elongation